LONDON (Reuters): GSK Plc said on Monday that its HIV-focused unit ViiV Healthcare’s cabotegravir injected drug and tablets got marketing authorisation from the European Medicines Agency.
Cabotegravir is recommended in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually-acquired HIV-1 infection in high-risk adults and adolescents weighing at least 35 kilogrammes, the company said.
F.P. Report MUZAFFARABAD : The situation in Azad Kashmir seemed to have calmed down as…
RIYADH: Kuwait formed a new cabinet headed by Ahmad Abdullah Al-Ahmad Al-Sabah, Kuwait News Agency…
ISTANBUL (AFP): Greece’s Prime Minister Kyriakos Mitsotakis will be received on Monday in Ankara by…
ISLAMABAD (APP): Pakistan and Uzbekistan Commodity Exchange leaders have agreed to adopt a joint future…
F.P. Report ISLAMABAD: President Asif Ali Zardari has urged all the stakeholders to exercise restraint…
F.P. Report LAHORE: Pakistan Peoples Party (PPP) Chairman Bilawal Bhutto Zardari has advised politicians to…
This website uses cookies.